Background: Wilson's disease (WD) is an autosomal recessive disorder of copper metabolism caused by ATP7B pathogenic mutations. The symptoms of WD can be effectively prevented if the affected individuals are identified and intervened early. However, clinical utility of this molecular analysis is challenging due to hundreds of variants with various clinical effects in the gene. Here, we aim to describe the spectrum of ATP7B variants and assess their clinical effects in the Han Chinese population. Methods: The ATP7B gene was directly sequenced in 632 unrelated WD patients and 503 unrelated healthy individuals. The effects of identified variants were classified according to the American College of Medical Genetics and Genomics (ACMG) standards and guidelines. Different frequency of variants observed in both cases and controls were tested using Chi-square or Fisher's exact tests. Results: We detected 161 non-synonymous variants in these 632 WD patients, 58 of which were novel. Among these variants, 78, 64, 8, 4 , and 7 were classified as 'pathogenic variants', 'likely pathogenic variants', 'variants with uncertain significance', 'likely benign variants', and 'benign variants', respectively. Ninety percent (569/632) of these WD patients can be genetically diagnosed with two or more 'pathogenic' or 'likely pathogenic' variants. The 14 most common disease-causing variants were found at least once in 94% (537/569) of genetically diagnosed patients. Conclusions: These data expand the spectrum of ATP7B variants and facilitate effective screening for ATP7B variants for early diagnosis of WD and development of individualized treatment regimens.
Introduction
Wilson's disease (WD, OMIM #277900), or progressive hepatolenticular degeneration, is an autosomal recessive disease caused by pathogenic mutations within the ATP7B gene. [1] [2] [3] ATP7B encodes a P-type ATPase that is involved in the transport of copper into the plasma protein ceruloplasmin (Cp) and in the ex-
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International Publisher cretion of copper from the liver. ATP7B protein malfunction leads to massive accumulation of copper in the liver, brain, and other tissues. The accumulation of copper in these areas can present a wide spectrum of symptoms, including liver cirrhosis; neuronal degeneration of the brain, particularly in the basal ganglia; Kayser-Fleischer (K-F) rings at the corneal limbus; and kidney damage. 4 The incidence of WD is estimated to be 1 in 30,000 individuals, and the heterozygous carrier rate is about 1 in 90 among many ethnic groups. 5 However, a recent study identified the genetic prevalence of WD as 1:7,026 in the United Kingdom by sequencing ATP7B in 1000 control subjects, 6 much higher than the typically reported prevalence of WD of 1:30,000. In addition, WD is thought to be more frequent in Asian populations. The presumed prevalence of WD is approximately 1 in 3,000 in the Korean population 7 and the expected frequency of WD is 1 in 5,400 in the Hong Kong Han Chinese population. 8 WD is among a limited number of inherited diseases for which symptoms can be prevented if the affected individuals can be identified and intervened early. However, accurate and early clinical diagnoses are often difficult to make due to the wide array of phenotypic variations. 9 While genetic analysis is feasible, its clinical utility has been limited due to more than 700 ATP7B reported variants with various clinical effects (https://portal.biobase-international.com/ hgmd/pro/gene.php?gene=ATP7B, Human Gene Mutation Database Professional, access date: 20 October, 2015). Therefore, better understanding of the spectrum of ATP7B variants and the clinical effects of these variants are necessary for clinical application.
Here, we reported variants identified from a study that directly sequenced the ATP7B gene in 632 consecutively treated WD patients at three Chinese academic medical centers between 2004 and 2015, and 503 unrelated phenotypically normal individuals. The clinical effects of identified variants were classified according to the American College of Medical Genetics and Genomics (ACMG) standards and guidelines.
Subjects and Methods

Participants
Consecutive patients who sought for diagnosis and treatment of WD between January 15, 2004 and April 30, 2015 at the Departments of Neurology at three leading Chinese academic medical centers were recruited, including Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou; First Affiliated Hospital, Fujian Medical University, Fuzhou; Huashan Hospital, Fudan University, Shanghai. Each patient was examined by at least two senior neurologists, including medical history review and physical exams. The patients were clinically diagnosed with WD according to the diagnostic criteria described previously. 4 Blood samples of 632 unrelated patients (346 males and 286 females, aged 9 to 56) who have average onset age of 18.5 ± 0.6 ranging from 3 to 48 years and 503 unrelated phenotypically normal controls with no known family history of WD were included in the study. Family history were detected in 16 out of 632 WD patients. All participants are of Han Chinese descent. The probands, or their legal guardians, provided informed consents. This study was approved by three institutional review boards.
Direct DNA Sequencing for Mutation Analysis of ATP7B
Genomic DNA was isolated from peripheral blood lymphocytes using a DNA isolation kit (Qiagen Inc, Valencia, CA). All 21 exons and their flanking regions as well as the 5'-untranslated region (UTR) and promoter regions of the ATP7B gene were sequenced. Exon 2, which is 1,234 base pair (bp) in length, was covered by three overlapping PCR fragments. The primer sequences, annealing temperatures, and sizes of the PCR products of exons 1, 2, 4, 16, and 18 were listed in Table S1 . Information related to the remaining primers has been described previously. 10 PCR amplification and direct sequencing were performed as previously reported. 11 Obtained sequences were compared, and nucleotide changes were numbered according to their position in ATP7B mRNA (NM_000053). Novel variants were further confirmed by sequencing both the forward and reverse strands. The sequence variants were interpreted and classified according to ACMG Standards and Guidelines. 12 
Statistical Analysis
Different frequency of variants observed in both WD patients and controls was tested using Chi-square test or the Fisher's exact test (for variants with the expected number of subjects below 5). The Bonferroni correction was used to declare statistical significance.
Results
Variants identified in the ATP7B Gene
A total of 173 variants in the coding region and the adjacent splice sites of the ATP7B gene were identified among 632 unrelated WD patients and 503 controls, including 161 non-synonymous and 12 synonymous variants. Among the 161 non-synonymous variants, 150 were detected only in WD patients and 11 were detected in both WD patients and normal controls. To assess link of the latter group of variants with WD, we compared allele frequency for 10 of these 11 variants between WD patients and controls (one of the 11 variants, p.R778L, was excluded because it is a well-established pathogenic variant 13 ). Three variants (p.I390V, p.T935M, and p.V1106I) were considerably more common in WD patients than controls and the differences reached a statistical significance level (p<0.005) after adjusting for 10 multiple tests (0.05/10) ( Table 1 
Classification of Variants
Among 161 non-synonymous variants, 7 were similar between cases and controls ( Table 1) , thus classified as benign variants according to the ACMG Standards and Guidelines. 12 The remaining 154 non-synonymous variants were only observed in WD patients or significantly more frequent in WD patients ( Table 2) . They are distributed throughout the ATP7B gene exons 1 to 21 (Figure 1 
Novel Variants
Among the 161 non-synonymous variants, 58 are novel and the chromatograms of these variants were illustrated in Figures 2A, 2B, 2C and 2D Similarly, the 4 nonsense variants could result in production of a shortened, dysfunctional protein. Table 3) . A homology search of the ATP7B protein in different species demonstrated that 32 missense variants occur within highly conserved regions of ATP7B protein (Figure 3) . In total, among 58 novel variants, 25 are classified as 'pathogenic variants', 26 as 'likely pathogenic variants', 5 as 'variants with uncertain significance' and 2 as 'likely benign variants'.
Most Common Variants
Among the 632 WD patients, 569 patients (90%) were identified with homozygous or compound heterozygous potential disease-causing variants, 58 patients (9%) with one heterozygous variant and other 5 patients (1%) did not have any potential disease-causing variant. Therefore, 90% (569/632) of patients can be genetically diagnosed with WD. Among the 142 potential disease-causing variants including 78 'pathogenic variants' and 64 'likely pathogenic variants', 14 were relatively common in the WD patient cohort, each with an allelic frequency 1% or higher. These 14 most common disease-causing variants were found in 94% (537/569) of genetically diagnosed WD patients with two or more 'pathogenic' or 'likely pathogenic' variants. The allelic frequencies and numbers of patients with each of these variant are presented in Table 4 . Notably, the three most prevalent variants, p.R778L, p.P992L and p.T935M, were detected at least once in 78% (445/569) of genetically diagnosed WD patients. The allelic frequencies of p.R778L, p.P992L and p.T935M are 0.319, 0.155 and 0.077, respectively; all of which are 'pathogenic variants'.
Patients with More than Two Variants
Six patients carried three disease-causing variants and their 3-variant genotypes are described in 
Discussion
In the present study, the prevalence of ATP7B variants was systematically investigated in the largest Chinese WD cohort to date, with 632 patients and 503 normal controls. One hundred and sixty-one non-synonymous variants within the ATP7B gene were found in WD patients, including 58 novel variants. This study catalogs ATP7B variants in Han Chinese WD patients and expands the spectrum of ATP7B variants.
Another major contribution of the study is the classification of ATP7B variants. Based on the type of alterations, their predicted impact, and frequency between WD cases and controls, these 161 non-synonymous variants are classified as 'pathogenic variants' (N=78), 'likely pathogenic variants' (N=64), 'variants with uncertain significance' (N=8), 'likely benign variants' (N=4), and 'benign variants' (N=7). The observation that 90% (569/632) of these WD patients had two or more 'pathogenic' or 'likely pathogenic' variants demonstrates the clinical utility of the catalog and classification of ATP7B variants.
The 14 most common disease-causing variants were found at least once in 94% (537/569) of genetically diagnosed patients. Notably, the three most prevalent pathogenic variants, p.R778L, p.P992L and p.T935M, were detected in 78% (445/569) of the patients. These results demonstrate the feasibility of developing a rapid and cost-effective genetic test such as multiplex allele-specific PCR to screen for WD.
We found 6 unrelated WD patients (1.1%) carrying three disease-causing variants, and which was reported previously in Caucasian populations. 6 This observation is important because it suggests that two disease-causing variants may reside in a chromosome. The implication is that if an individual carries two disease-causing variants but his/her clinical features do not support the diagnosis of WD, it is necessary to test these variants in parents to identify the specific location of them. If the two variants reside in a chromosome, the individual is a heterozygous carrier and cannot be genetically diagnosed. If two variants reside in different chromosomes, then a genetic diagnosis of WD can be made.
According to ACMG Standards and Guidelines, 12 we classified 4 variants as 'likely benign' variants, one of which (p.Q1142H) was previously considered as a pathogenic variant. 14 Tsai et al. found that Q1142 was located at the ATP pocket of ATP7B protein, and the amino acid replacement of the site would directly disrupt ATP7B function. However, the amino acid change in p.Q1142H was predicted to be tolerated by SIFT (score: 0.16) and benign by PolyPhen-2 (score: 0) software programs, this variant should be considered as 'likely benign'. This finding is important because the variant is relatively frequent and found in 19 WD patients (18 heterozygous and one homozygous). Caution should be made in interpreting the carrier of the Q1142 variant to avoid misdiagnosis and unnecessary treatment.
Sixty-three clinically diagnosed WD patients cannot be genetically diagnosed with WD because they were detected to carry only one disease-causing variant or none. Several factors may induce the observation. First, a subset of these 63 patients may have been misdiagnosed. For example, these patients may have been included in the patient cohort on the basis of false positive K-F rings. Second, large hemizygous deletions may occur in a subset of these patients and these alterations are difficult to be detected using the Sanger sequencing method. In fact, a hemizygous large deletion spanning the exon 20 and adjacent introns has previously been reported. 15 Other methods such as multiplex ligation-dependent probe amplification (MLPA) may be used to detect large deletions. Third, other genetic alterations outside the ATP7B coding region and adjacent splice sites as well as other cellular factors associated with WD may contribute to the clinical development of WD in these patients. 16 In conclusion, the current study considerably expands the spectrum of ATP7B variants and provides classification of their clinical effects. These results improve the genetic diagnosis of suspected WD patients and facilitate genetic screening for WD among asymptomatic children in the general Chinese population.
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